CureFAKtor Pharma is intending to conduct a Phase I clinical study of CFAK-C4 in combination with gemcitabine chemotherapy in 2012.
CureFAKtor Pharma president and CEO Shep Wild said receiving Orphan Drug Designation by the FDA is an important milestone for CureFAKtor, as well as for pancreatic cancer patients who have the lowest survival rate of any cancer and limited treatment options.
"CFAK-C4 is the first clinical candidate derived from our broad FAK technology platform and we look forward to progressing CFAK-C4 into human clinical trials," Wild said.